Our experts process eligible umbilical cords and placenta tissue in our state of the art ISO Class 3 laboratory facility to develop non-embryonic stem cell-derived products. We use our minimally manipulative proprietary techniques to extract valuable bioactive biomolecules from the Wharton’s Jelly stem cells and its extracellular matrix following FDA tissue guidelines, current good manufacturing practice (cGMP), and current good tissue practice (cGTP). Our technology allows us to achieve high levels of quality, purity, potency, viability, reproducibility (batch to batch consistency), and safety. The result is extremely high quality, effective clinical grade stem cell-derived products.

Consistent quality is our main goal. Our products undergo extensive in-house and third-party laboratory quality control and validation testing through universities to meet our quality standards. Only qualified products are distributed to doctors and clinics nationwide.

Injectables need to be stored below a minimum of -80˚C using either a cryo-freezer or a liquid nitrogen freezer. Freezing and thawing process is stressful to biological products and they can cause complete loss of potency if done incorrectly. To overcome this problem, we have successfully developed proprietary fluidless rate controlled freezing, packaging, and shipping techniques to preserve the integrity and potency of our products to its maximum. For best results, we also recommend clinicians to thaw  products at room temperature (counter thawing).